Covetrus Past Earnings Performance
Past criteria checks 0/6
Covetrus's earnings have been declining at an average annual rate of -7.8%, while the Healthcare industry saw earnings growing at 15.3% annually. Revenues have been growing at an average rate of 7.1% per year.
Key information
-7.8%
Earnings growth rate
-9.8%
EPS growth rate
| Healthcare Industry Growth | 15.7% |
| Revenue growth rate | 7.1% |
| Return on equity | -0.9% |
| Net Margin | -0.3% |
| Last Earnings Update | 30 Jun 2022 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Covetrus makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 22 | 4,649 | -13 | 723 | 0 |
| 31 Mar 22 | 4,621 | -40 | 728 | 0 |
| 31 Dec 21 | 4,575 | -54 | 714 | 0 |
| 30 Sep 21 | 4,575 | -56 | 709 | 0 |
| 30 Jun 21 | 4,539 | -90 | 714 | 0 |
| 31 Mar 21 | 4,376 | -13 | 685 | 0 |
| 31 Dec 20 | 4,339 | -26 | 698 | 0 |
| 30 Sep 20 | 4,225 | -19 | 700 | 0 |
| 30 Jun 20 | 4,117 | -940 | 630 | 0 |
| 31 Mar 20 | 4,100 | -996 | 688 | 0 |
| 31 Dec 19 | 3,976 | -980 | 661 | 0 |
| 30 Sep 19 | 3,871 | -948 | 576 | 0 |
| 30 Jun 19 | 3,776 | 27 | 587 | 0 |
| 31 Mar 19 | 3,772 | 65 | 504 | 0 |
| 29 Dec 18 | 3,778 | 101 | 485 | 0 |
| 30 Sep 18 | 3,791 | 69 | 547 | 0 |
| 30 Jun 18 | 3,776 | 74 | 543 | 0 |
| 31 Mar 18 | 3,649 | 67 | 532 | 0 |
| 30 Dec 17 | 3,580 | 64 | 460 | 0 |
| 31 Dec 16 | 3,353 | 70 | 489 | 0 |
| 26 Dec 15 | 2,978 | 60 | 418 | 0 |
Quality Earnings: 2NJ is currently unprofitable.
Growing Profit Margin: 2NJ is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 2NJ is unprofitable, and losses have increased over the past 5 years at a rate of 7.8% per year.
Accelerating Growth: Unable to compare 2NJ's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 2NJ is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (-16.1%).
Return on Equity
High ROE: 2NJ has a negative Return on Equity (-0.85%), as it is currently unprofitable.